YOLFTbeta
22

Genomictree Inc.

228760 · KQ · Healthcare / Biotechnology

8,930.00KRW-230.00 (-2.51%)

Price History

Full chart

Market Stats

Previous Close9,160.00
Open9,160.00
Day Range8,800.00 – 9,400.00
52-Week Range9,930.00 – 33,300.00
Volume61.41K
Market Cap299.20B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.09
50-Day Avg11,625.00
200-Day Avg16,874.00

About

Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases. The company offers EarlyTect C, a screening method for early diagnosis of colorectal cancer; EarlyTect L for detection of epigenetic markers associated with lung cancer in pulmonary nodule patients; and EarlyTect B for detection of genetic and epigenetic markers associated with bladder cancer in hematuria patients. It also provides AccuraDTect SARS-CoV-2 RT-qPCR kits, test providers, and nucleic acid transport medium products. The company was founded in 2000 and is headquartered in Daejeon, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Sung-Whan An
  • Employees79
  • Headquarters44-6 Techno 10-ro, Daejeon, South Korea, 34027, Korea
  • Websitehttps://genomictree.com

Leadership

  • Mr. Chi-Wang YoonCOO & VP · b. 1962
  • Dr. Sung-Whan AnCEO & President · b. 1961
  • Hong Sun LeeHead of Management Support Headquarters & CFO
  • Dr. Tae-Jeong Oh Ph.D.Head of R&D Division · b. 1966
  • Un Lee YongHead of Business Division
  • Soon Kim MyungHead of Molecular Diagnostic Lab

Financials

Income Statement

Currency: KRW2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-266.33M1.24B5.14B29.87B3.42B2.36B3.76B
Growth (%)--+365.16%+314.87%+481.09%-88.56%-30.89%+59.17%
Cost of Revenue-782.07M1.18B2.62B4.87B3.69B3.09B3.05B
Gross Profit--515.75M55.22M2.52B24.99B-270.02M-726.56M713.90M
Gross Margin--193.65%4.46%48.93%83.69%-7.90%-30.76%18.99%
Operating Expense-11.83B12.46B12.37B20.71B12.48B14.59B12.01B
Operating Income--12.34B-12.41B-9.86B4.28B-12.75B-15.31B-11.30B
Operating Margin--4635.28%-1001.61%-191.75%14.34%-372.88%-648.24%-300.47%
EBITDA----3.02B-6.27B-8.91B-7.71B
EBITDA Margin----10.13%-183.47%-377.14%-205.07%
Net Income--9.60B-11.80B-11.42B-6.63B-8.76B-10.24B-8.99B
Net Income Margin--3603.55%-952.10%-222.28%-22.20%-256.17%-433.57%-238.98%
R&D-1.98B3.51B2.81B5.45B4.37B4.94B3.79B
R&D as % of Total Revenue-745.10%283.33%54.70%18.23%127.73%209.21%100.75%
Interest Expense--1.67B4.61B5.38B2.05B294.65M338.07M
Interest Expense % of Total Revenue--134.67%89.61%18.02%60.10%12.47%8.99%

Balance Sheet

Currency: KRW2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets--117.90B177.15B162.91B132.84B130.68B120.76B
Total Liabilities--22.64B62.05B55.86B7.81B6.36B5.45B
Total Equity--95.26B115.10B107.05B124.74B123.88B115.07B
Cash--56.64B66.46B67.57B45.27B26.35B16.31B

Cash Flow

Currency: KRW2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-2.08B-8.77B-10.19B-7.63B4.29B-10.88B-13.63B-10.19B
Investing Cash Flow-202.66M-59.49B14.26B-14.07B8.12B-11.49B-
Financing Cash Flow5.76B103.77B12.98B--19.52B-20.50B6.02B-
Capital Expenditure2.69B2.24B2.68B11.83B1.82B288.40M2.55B2.75B
Free Cash Flow---12.97B-19.46B2.46B-11.17B-16.19B-12.94B
FCF to OCF--127.31%255.00%57.44%102.65%118.72%126.94%

Earnings

Report DateJun 30, 2018Sep 30, 2018Dec 31, 2018May 14, 2019Aug 14, 2019Nov 14, 2019Mar 16, 2020May 14, 2020Aug 14, 2020Nov 13, 2020Feb 22, 2021May 14, 2021Aug 13, 2021Nov 12, 2021Feb 16, 2022Mar 31, 2022Jun 30, 2022Nov 11, 2022Feb 9, 2023Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate-----------276.00-480.00---------------------
EPS Actual-36.29-36.01-51.10-325.25-32.4835.77-245.13-238.00-109.00-178.00-66.00-106.00-73.00-231.00-140.76567.97-461.96-182.29-246.25-150.45-87.72-124.09-59.31-118.31-117.64-129.24-71.64-121.36-58.91-113.40-80.75-80.20-100.58
Surprise----------76.09%77.92%---------------------
Timing---Pre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hours--Pre-marketAfter-hours--------------

Key Statistics & Ratios

Market Cap299.20B
Enterprise Value190.86B
Trailing P/E0.00
Forward P/E0.00
Price / Sales101.55
Price / Book2.22
Revenue (TTM)2.95B
Gross Profit (TTM)-164.40M
EBITDA-10.55B
Profit Margin0.00%
Operating Margin-313.90%
Return on Equity-7.69%
Return on Assets-5.92%
Shares Outstanding24.54M
Shares Float20.70M
Beta0.09
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Sep 14, 20182:1
  • Nov 9, 20173:1